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Abstract
Prion diseases have been linked to impaired copper homeostasis and copper induced-oxi-
dative damage to the brain. Divalent metal ions, such as Cu2+ and Zn2+, bind to cellular
prion protein (PrPC) at octapeptide repeat (OR) and non-OR sites within the N-terminal half
of the protein but information on the impact of such binding on conversion to the misfolded
isoform often derives from studies using either OR and non-OR peptides or bacterially-
expressed recombinant PrP. Here we created new transgenic mouse lines expressing PrP
with disrupted copper binding sites within all four histidine-containing OR’s (sites 1–4,
H60G, H68G, H76G, H84G, "TetraH>G" allele) or at site 5 (composed of residues His-95
and His-110; "H95G" allele) and monitored the formation of misfolded PrP in vivo. Novel
transgenic mice expressing PrP(TetraH>G) at levels comparable to wild-type (wt) controls
were susceptible to mouse-adapted scrapie strain RML but showed significantly prolonged
incubation times. In contrast, amino acid replacement at residue 95 accelerated disease
progression in corresponding PrP(H95G) mice. Neuropathological lesions in terminally ill
transgenic mice were similar to scrapie-infected wt controls, but less severe. The pattern of
PrPSc deposition, however, was not synaptic as seen in wt animals, but instead dense
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globular plaque-like accumulations of PrPSc in TgPrP(TetraH>G) mice and diffuse PrPSc
deposition in (TgPrP(H95G) mice), were observed throughout all brain sections. We con-
clude that OR and site 5 histidine substitutions have divergent phenotypic impacts and that
cis interactions between the OR region and the site 5 region modulate pathogenic outcomes
by affecting the PrP globular domain.
Introduction
Prion diseases such as Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
are progressive neurodegenerative disorders that are caused by the structural conversion
and aggregation of the normal cellular prion protein (PrPC) to a misfolded, partially prote-
ase-resistant isoform (PrPSc) [1]. Structurally, PrPC consists of a globular folded C-terminal
domain, which is largely α-helical, and a glycine-rich N-terminal domain containing an
octapeptide repeat region (OR) composed of four contiguous copies of the highly conserved
PHGGGWGQ sequence [2]. The mechanistic details of replication and disease pathogenesis
are not understood in detail, but appear to involve direct interaction between PrPC and
PrPSc [3, 4]. In this context, the intrinsically disordered N-terminal domain of PrPC is sug-
gested to play a role in modulating the physiological function of PrPC as well as altering
pathological outcomes in prion diseases [1, 5–7]. A multitude of studies demonstrates that
the N-terminus of PrP can interact with a broad range of ligands, such as β-sheet-rich con-
formers (in particular, PrPSc and Alzheimer’s Disease Aβ42 peptide), metal ions (such as
Cu2+ and Zn2+), lipids, nucleic acids, and glycosaminoglycans, which confer to the protein
diverse, and sometimes contrasting, activities, including protection from oxidative stress
and intermediation of the toxic effects of PrPSc (reviewed in [8]). At physiological pH, the
N-terminal domain can selectively bind up to six Cu2+ ions with the first 2 molar equiva-
lents of Cu2+ binding to the amyloidogenic region of human PrPC containing His-96 and
His-111 (“site 5”), and then to the four binding sites provided by the OR region [8, 9].
Despite numerous studies, it is unclear whether copper binding to PrP promotes or pre-
vents prion diseases. It was found earlier, that the presence of copper greatly slows amyloid for-
mation [10] and that the addition of copper reduces the accumulation of PrPSc [11]. Moreover,
under physiologically-relevant low Cu2+ levels, binding of copper to the OR region enhances
the structural stability of the whole N-terminal domain making it more resistant to misfolding
[12]. These findings suggest a protective role for copper at the initial stages of prion diseases
when bound in the low-occupancy mode. On the other hand, reduction of copper levels in the
brain by chelation attenuates the onset of prion disease [13].
More recent findings suggest that distinct redox activities of a copper-bound PrP are
involved in the mechanisms underlying prion diseases [14]. In particular, the histidine-rich
copper-binding complex derived from the OR region has been shown to exhibit a high reduc-
tion potential for the Cu(II)/Cu(I) couple and tends to stabilize the lower-valent Cu(I) state,
which can initiate reactions leading to reactive oxygen species (ROS)-mediated events, includ-
ing β-cleavage [15–19]. Following ROS-mediated β-cleavage at Gly90, further Cu2+ coordina-
tion to the potential copper binding sites His96 and His111 in human PrP (equivalent to
mouse residues 95, 110) can induce localized β-sheet secondary structure, which may subse-
quently proceed into the C-terminal domain [20–22]. The copper-binding site 5 around His96
in turn exhibits a high oxidation potential for the Cu(II)/Cu(III) couple and stabilizes the
higher-valent Cu(III) state which is involved in early events that initiate the misfolding
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pathway. Notably, alterations of the number of octapeptide repeats [23, 24] have been shown
to abrogate the Cu2+-dependent endocytosis of PrP, indicating that, although there are non-
octarepeat Cu2+-binding sites in PrPC, it is binding of the metal at the octapeptide repeats that
is essential for its internalization. Thus, loss of Cu2+-mediated endocytosis of PrPC may also
contribute to the disease phenotype.
Information on the role of metal ion binding to PrP and its impact on the conversion to the
aberrant isoform is skewed towards studies utilizing either peptides corresponding to the
octarepeats or bacterially-expressed recombinant PrP (rPrP). Based on the concept that the N-
terminal region of metal-free PrPC is natively unstructured but that different stoichiometries
of metal binding can impart different structures upon the OR [25], Lau et al. recently created
new PrP alleles which either lock the OR in an extended conformation conductive to binding
up to 4 copper ions per OR or in a compact conformation that can only bind one copper ion
per OR [26] to restrict inter-conversion and study their biological properties individually. In
this study, we altered the OR and binding sites 1–5 in a different way, by substituting the histi-
dine residues with glycine in order to prevent loading of metal ions ("metallation"), and moni-
tored the formation of misfolded PrP in vivo in these newly generated transgenic mice.
Material and methods
Generation of transgenic mice
We used a derivative of the half-genomic vector phg-Prnp [5, 27] designated phg-Sce1 wherein
a 3000 bp KnpI-NarI-fragment, which contains the entire Prnp ORF and part of the 3’-UTR
was modified by using by a synthetic double-stranded I-SceI recognition sequence derived
from the complementary primer pair 5’-CGCCTAGGGATAACAGGGTAATGTAC-3’ and
5’-ATTACCCTGTTATCCCTA-GG-3’ (a gift from H. Jacobsen). XhoI-XbaI-fragments from
pCi-PrP-TetraH>G and pCi-PrP-H95G, respectively [28], comprising the mutant Prnp ORFs
were treated with T4-DNA polymerase to fill in 5’-overhangs at both ends and ligated into the
phg-Sce-I vector, which had been cleaved with I-SceI and treated with S1-nuclease to remove
3’-overhanging nucleotides. From these plasmids, called phg-PrP-TetraH>G and phg-
PrP-H95G, respectively, a NotI-SalI fragment was injected into the male pronucleus of fertil-
ized oocytes. Blastulae were transferred to the uteri of foster mothers according to standard
techniques. This procedure and the initial screening of tail biopsies of the offspring for the
integration of the desired transgene were performed at RCC Ltd (Fu¨llinsdorf, Switzerland). To
screen founders, genomic DNA was extracted from tail biopsies and used as template for PCR
reactions employing primer pair Exon2 (5’-caaccgagctgaagcattctgcct-3’) and
Mut217 (5’-cctgggactccttctggtactgggtgacgc-3’). Transgenic animals were
characterized by the generation of a 700 bp fragment during these reactions. Founders gener-
ated on a 129Sv genetic background were identified and crossed back into PrP-/- mice (C57BL/
6J × 129/Sv genetic background; [28]) to yield Prnp0/0 lines homozygous for the PrP-encoding
transgene array. In doing so, one Prnp0/0 lines homozygous for the PrP(TetraH>G)-encoding
transgene array, designated lines 34, and three Prnp0/0 lines homozygous for the PrP(H95G)-
encoding transgene array, termed lines 4, 11, and 13, respectively, were identified.
Intracerebral inoculations and scrapie diagnosis
Groups of eight mice each comprising PrP(TetraH>G)+/+ mice (lines 34) as well as PrP
(H95G)+/+ mice of three different founders on PrP-/- background (lines 4, 11, and 13) and
wild-type mice (C57BL/6J × 129Sv genetic background), respectively, were intracerebrally (i.
c.) inoculated with mouse-adapted scrapie strain RML (NIH Rocky Mountain Laboratory,
Hamilton, MT) using a dose of 30 μl of 10% (w/v) brain homogenate in sterile phosphate
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buffered saline (PBS). In parallel a 10% (w/v) brain homogenate from uninfected control
mice ("mock" homogenate) was used. Inoculation was performed with a Luer lock system
(catalog #807.001C; Robert Helwig, Berlin, Germany), and diethylether was used as an anes-
thetic. At that time the experiments were performed, the use of diethylether to anesthetize
mice followed the animal protection regulations at the Ludwig Maximilians University but
we note that ether is not any longer advised for use in this role due to potential adverse
effects. All animals were kept under standard diurnal pathogen-free conditions and allowed
access to food and water ad libitum. Mice were monitored every second day for the onset of
clinical symptoms, and TSE was diagnosed according to standard clinical criteria used to
identify animals exhibiting signs of scrapie, including ataxia, kyphosis, and hind leg paresis
[29, 30]. Mice were euthanized at the onset of clinical signs associated with terminal prion
disease and extracted brain tissues were subjected to histopathological analyses. The animal
experiments were performed in accordance with animal protection standards and were
approved by the government of Upper Bavaria (protocol number 209.1-2531-31/02). Every
effort was made to reduce the number of animals used and to ensure they were free of pain
and discomfort.
For secondary passage 30 μl of 10% (w/v) brain homogenate derived from terminally-dis-
eased PrP(TetraH>G)+/+ mice (line 34, mouse #258 and #260, respectively) primarily inocu-
lated with RML prions were i.c. injected in healthy C57BL/6J 129Sv and PrP(TetraH>G)+/+
mice (n = 8 each). In a parallel experiment, 30 μl of 10% brain homogenate derived from two
terminally-diseased RML-infected PrPH95G+/+ mice (line 13, mouse #304 and #205) were i.c.
inoculated in healthy wild-type and PrP(H95G)+/+ mice, respectively.
Histopathology and immunohistochemistry
Brains from terminally diseased mice were fixed with 4% buffered formalin, subsequently
inactivated with 100% formic acid for 1 h, paraffin-embedded and then subjected to routine
staining procedures using a Benchmark staining machine with a standard 3’,3-diaminoben-
zidine (DAB) detection system according to the manufacturer’s instructions (Ventana Med-
ical Systems, Arizona, USA). For detection of PrPSc monoclonal CDC1 antibody raised
against full-length mouse PrP was used (1: 500 in PBS-Tween). Spongiform changes and
gliosis were visualized using Hematoxylin and Eosin staining and anti-GFAP polyclonal
antiserum (1:1600, DAKO, Germany), respectively. Histological sections were scored in a
blinded fashion for spongiform changes in nine standard grey matter areas and three white
matter areas as described earlier [31, 32] and lesion profiles were constructed [33, 34]. Scor-
ing of pathological change was performed in the same regions using the following score: 0 =
“not detectable”, 1 =“mild”, 2 =“medium”, 3 =“high”, for levels of gliosis or PrPSc deposi-
tion, respectively.
Histoblotting
Paraffin-embedded-tissue (PET)-blots were prepared as described [35]. In brief, formic acid-
decontaminated tissue samples were embedded in paraffin. Thereafter, 4–7 μm paraffin sec-
tions were mounted on prewetted 0.45 μm nitrocellulose membrane (Bio-Rad, Munich, Ger-
many). Protease-resistant PrPSc (after digestion with 250 μg/ml proteinase K overnight at
55˚C) and total PrP (no proteinase K digestion) were detected using monoclonal CDC1 anti-
body (1:2000) and goat anti-rabbit secondary antibody (1:1000). Visualization was performed
using 4-nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate
(BCIP) (Boehringer Mannheim, Germany).
PrP alleles with mutated histidine residues
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Determination of PrPSc by western blotting
Brain homogenates were made to 10% (w/v) with lysis buffer (100 mM NaCl, 10 mM EDTA,
0.5% Nonidet P-40, 0.5% sodium deoxycholate, 10 mM Tris, pH 7.6) using a Dounce homoge-
nizer (Schuett-biotec GmbH, Go¨ttingen, Germany). Samples were treated with proteinase K
(1 μg/ 10 μl lysate) at 37˚C for 30 min and/or PNGase F (New England BioLabs, Frankfurt,
Germany) according to the manufacturer´s protocol. Digestion was terminated by boiling in
Laemmli sample buffer. Proteins were size-fractionated on a sodium dodecyl sulphate-15%
polyacrylamide gel (SDS-PAGE) and transferred to Immobilon-P nitrocellulose membranes
(0.2 μm; Millipore, Schwalbach, Germany) by semidry blotting. Membranes were blocked
with 5% non-fat dry milk in PBS-T (PBS containing 0.1% Tween-20) for 2 h at room tempera-
ture and subsequently incubated with monoclonal antibody 4H11 [36], 6H4 (Prionics, Schlie-
ren-Zurich, Switzerland) or SHA31 (Medicorp, Montreal, QC, Canada) overnight at 4˚C.
Following washing with PBS-Tween (PBS-T), the membranes were incubated with horseradish
peroxidase-linked goat anti-mouse IgG (1:3000; GE Healthcare, Freiburg, Germany) for 1 h at
room temperature. After washing the membranes again with PBS-T and incubating them with
alkaline phosphatase buffer (100 mM NaCl, 5 mM MgCl2, 100 mM Tris; pH 9.5) for 10 min at
room temperature, the antigen was detected with CPD-Star (Roche, Mannheim, Germany).
Quantification was performed using AIDA 3.26 image analysis software (Raytest, Strauben-
hardt, Germany).
Cell-free conversion of 35S-labelled PrPC
Adherent rabbit kidney epithelial (RK13) cells [37] were co-transfected with vectors
pcDNA3.1/Hygro(+) (Invitrogen) and pCI-neo (Promega) carrying either full-length mouse
PrP or PrP(TetraH>G) as described previously [38]. Single cell clones resistant to hygromycin
B (500 μg/ml, Roche) were expanded and the level of PrPC expression was monitored by west-
ern blot analysis after SDS-PAGE of cell lysates.
Labelling of PrPC with 35S and purification of PrPC from cell lysates was performed as
described previously [38]. Briefly, cell clones were incubated for 1 h at 37˚C with 5% CO2 in
culture medium lacking cysteine and methionine. Tunicamycin was also added in a concentra-
tion of 27 μg/ml in order to obtain deglycosylated PrPC. After 1 h starvation, Redivue-Promix
(GE Healthcare, Munich, Germany) containing 35S-methionine and 35S-cysteine was added at
0.23 mCi/ml. Cells were lysed after 5 h incubation at 37˚C with 5% CO2. Lysates were centri-
fuged for 5 min at 4˚C at 1000 × g, the supernatant precipitated with four volumes of cold
methanol and the pellet resuspended into a detergent lipid protein complex (DLPC) buffer
(150 mM NaCl, 50 mM Tris/HCl pH 8.0, 2% N-laurylsarcosine, 0.4% L-α-phosphatidylcho-
line) by sonicating three times for 20 s with 70% output intensity using the ultrasound-genera-
tor Sonoplus HD2200-UW2200 with BR30 cup-horn sonicator (Bandelin, Berlin, Germany).
PrPC was purified from the DLPC suspension by immunoprecipitation as described by
Caughey et al. [39] using the antibody RA3153 [40]. PrPC was eluted from the protein-A
sepharose beads with 0.1 M acetic acid, transferred into 1.5 ml low-binding tubes (Eppendorf,
Hamburg, Germany) and stored at 4˚C. The activity of purified PrPC samples was measured
using the β-counter TRI-CARB 2900TR (Perkin Elmer, Rodgau, Germany). Purification of
PrPSc was performed as described previously [41]. The final pellet was resuspended in phos-
phate buffered saline (PBS) with 0.5% zwittergent sulfobetaine 3–14 (100 μl/2 g brain tissue)
by sonication. The resulting suspension was transferred into 1.5 ml low-binding tubes (Eppen-
dorf, Hamburg, Germany) and stored at 4˚C. PrPSc was purified from brains of terminally-dis-
eased tga20 mice infected with RML.
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In vitro conversion reactions with purified PrPSc and 35S-labeled PrPC were performed in a
reaction volume of 30 μl as described previously [38]. Briefly, 15,000 cpm 35S-PrPC was incu-
bated for 3 days at 37˚C with 4 μl of PrPSc in conversion buffer (200 mM KCl, 5 mM MgCl2,
0.625% N-laurylsarcosine, 50 mM sodium citrate pH 6.0) including 0.7 M guanidine hydro-
chloride (GndHCl). 90% of the reaction volume was digested with proteinase K (PK) for 1 h at
37˚C (20 μg/ml) and the remaining 10% was left untreated. Further sample preparation was
performed as described [39]. After electrophoresis of untreated and PK-digested samples gels
were incubated in fixing solution (isopropanol, H2O and acetic acid in a ratio (v/v) of 25:65:10,
respectively) for 30 min and subsequently incubated in Amplify (Amersham Biosciences, Frei-
burg, Germany) for additional 30 min. Pre-treated gels were dried and exposed using a Fuji-
film Phosphorimager BAS 1800 II and analyzed with AIDA V3.44.035 densitometry software
(Raytest, Straubenhardt, Germany). The band intensity of the samples with (I˚+PK) and with-
out (I˚-PK) PK treatment were measured after background subtraction. With respect to sam-
ples treated with proteinase K, only bands within the molecular weight range of 18–24 kDa
were used for evaluation. The conversion efficiency (CVE) was calculated using the formula
CVE [%] = [I˚+PK˚/˚(I˚-PK
10)]100.
In vitro aggregation of recombinant PrP
Production of recombinant full-length PrP. Recombinant full-length mouse PrP with
histidine (wt rPrP) or glycine at positions 60, 68, 76, and 84 (rPrP(TetraH>G)), and 95 (rPrP
(H95G)), respectively, was produced and purified essentially as described by Giese et al. [42]
except that for bacterial expression, BL21(DE3) RIL Escherichia coli cells (Novagen) were
transformed with plasmids pET17b-PrP23-230 for full-length wt-rPrP, pET17b-TetraH>G-
PrP23-230 for TetraH>G-rPrP, pET17b-H95G-PrP23-230 for H95G-rPrP or pET17b-PrP89-
230 and pET17b-H95G-PrP89-230 for N-terminal truncated wt-rPrP and H95G-rPrP. Fur-
thermore, for full-length and N-terminal truncated mutant PrPs the nickel-chelate affinity
chromatography step was replaced by gel filtration using a Sephadex S-75 HighPrep 16–26 col-
umn (GE Healthcare, Munich, Germany) equilibrated with a buffer containing 8 M urea, 10
mM MOPS, pH 7.0, and 150 mM NaCl. Fractions containing purified rPrP were pooled, con-
centrated with a Centriprep device (Millipore, Schwalbach, Germany) and diluted 1:50 for
refolding into 10 mM MES, pH 6.0. Solutions of refolded rPrP were stirred at 4˚C for 4–12 h,
and aggregates were removed by centrifugation for 30 min at 17,000 rpm at 4˚C. Supernatants
were concentrated again using Centriprep YM10 ultrafiltration cells (Merck Millipore, Darm-
stadt, Germany) and cleared from aggregates by centrifugation at 16,000 × g for 30 min at 4˚C.
Recombinant PrP was finally dialyzed against 2 mM MES, pH 6.0, to remove traces of urea
and imidazole. Correctness of the α-helical fold of the purified rPrPs was checked by CD-spec-
troscopy using a Jasco 715 CD-spectrophotometer. All amino acid numbers refer to the mouse
PrP sequence (GenBankTM accession number NP 035300).
Fluorescent labelling of rPrP. After buffer-exchange by gel filtration on a microspin col-
umn (Mobitec, Go¨ttingen, Germany) filled with Sephadex G15 (Pharmacia Biotech, Sweden)
pre-equilibrated with 10 mM sodium phosphate buffer (NaPi), pH 6.0, containing 0.1% NP40
(Sigma-Aldrich, Munich, Germany) for two minutes at 700 × g, NaHCO3 was added to a final
concentration of 100 mM. Protein labelling was performed with amino-reactive fluorescent
dyes Alexa Fluor-488-O-succinimidylester and Alexa Fluor-647-O-succinimidylester (Molecu-
lar Probes, Invitrogen, Karlsruhe, Germany) were performed exactly as described in Giese
et al. [42].
FCS/SIFT measurements. FCS and SIFT measurements were carried out on an Insight
Reader (Evotec-Technologies, Germany) with dual-color excitation at 488 and 633 nm using a
PrP alleles with mutated histidine residues
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40× of 1.2 NA microscope objective (Olympus, Japan) and a pinhole diameter of 70 μm at
FIDA setting exactly as described in Giese et al. [42]. The fluorescence data were analyzed by
correlation analysis using the FCSPPEvaluation software version 2.0 (Evotec OAI, Germany).
Two color cross-correlation amplitudes G(0) were determined using the same software. Evalu-
ation of SIFT data in two-dimensional intensity distribution histograms was performed as
described [42].
Aggregation assay. A stock solution of fluorescently-labeled rPrP was prepared in 10 mM
NaPi, pH 7.2, containing 0.2% sodium dodecyl sulfate (SDS, Sigma) to keep the protein in an
unaggregated state at the beginning of the measurements. The concentrations of rPrP-A-
lexa488 and rPrP-Alexa647 were adjusted to approximately 10 molecules per focal volume and
20 molecules per focal volume, respectively. Experiments were started by diluting this stock
solution into NaPi-buffer containing 0–0.2% SDS to obtain final SDS concentrations ranging
from 0.0125% to 0.2% and a final concentration of labeled rPrP of approximately 5 nM. In
some experiments, metal ions (CuCl2, MnCl2) or EDTA were added to the stock solutions of
monomeric rPrP in 0.2% SDS. Experiments were performed in 96-well plates with a cover
slide bottom (Evotec Munich, Germany). To reduce evaporation, the 96-well plates were sealed
with adhesive film. Typically, aggregation was monitored for 8 h in four parallel identical sam-
ples for each experimental group.
Statistics
Statistical analysis and graphics were done with SigmaStat 2.03, SigmaPlot 6.0 and Microsoft
Excel. Data of two independent groups following a normal distribution with equal variances
were analyzed with the unpaired Student´s t-test, p 0.05 was considered statistically
significant.
Results
Generation and characterization of PrP transgenic mice
We generated transgenic mouse lines encoding full-length mouse PrP with all four histidine
residues within the OR region (PrP(TetraH>G)) or at position 95 (PrP(H95G)) replaced with
glycine. To this we used the “half genomic” vector, wherein the protein coding sequence of
interest is placed under the control of the mouse Prnp promoter [5]. Constructs were microin-
jected into fertilized oocytes on a PrP knockout genetic background (Prnp0/0, 129/Sv-C57/
Bl6), with offspring of four founder lines expanded for further study. PrP(TetraH>G) (line 34)
and PrP(H95G)(line 13) mice were examined in detail and found to express the mutant pro-
teins in the brain at a level comparable to full-length PrPC in wt control mice (Fig 1A). More-
over, deglycosylation revealed that PrPC encoded by the PrP(TetraH>G) and PrP(H95G)
transgenes was represented by a C1 endoproteolytic fragment as well as full-length protein (i.e.
was processed in a manner analogous to that of wt PrPC; Fig 1B). Notably, transgenic mice pre-
sented with a wild-type-like distribution of mutant PrPC in the brain, and showed no signs of
spontaneous neurodegeneration for an observation period of up to 600 days (exemplarily
shown in S1 Fig).
When assessed in transfected RK13 cells (S2A Fig), in sucrose gradient fractionations the
TetraH>G version of PrP behaved like PrPC controls and segregated with raft fractions identi-
fied by cholera toxin B binding (S2B Fig). Interestingly, however, the TetraH>G allele showed
a diminished ability to transduce a toxic signal associated with the accumulation of PrPSc;
when SH-SY5Y cells expressing this allele were co-cultivated in the presence of chronically
infected N2a neuroblastoma cells they showed a lower tendency to undergo apoptosis than
their wt PrP-expressing counterparts (S3 Fig).
PrP alleles with mutated histidine residues
PLOS ONE | https://doi.org/10.1371/journal.pone.0188989 December 8, 2017 7 / 26
Susceptibility of mice expressing mutant PrP to scrapie prions
To examine the susceptibility of the novel transgenic mice to scrapie, mice descended from
PrP(TetraH>G) founder animals (line 34) as well as corresponding wt controls (129/Sv-C57/
Bl6) were inoculated intracerebrally (i.c.) with mouse-adapted Rocky Mountain Laboratory
(RML) prion isolate and monitored for the onset of disease-associated symptoms and for sur-
vival. Similarly, mice descended from three different PrP(H95G) founders (lines 4, 11, and 13)
were also subjected to prion challenge. We found that TgPrP(TetraH>G) mice were suscepti-
ble to scrapie, but succumbed to disease significantly later than wt controls (Table 1, "primary
passages"). Clinical signs did not appear until 292 days post infection (dpi; line 34), indicating
protracted disease duration, but were otherwise similar to those of RML-infected wt mice,
with signs including ataxia, kyphosis and difficulties in righting. In contrast, TgPrP(H95G)
mice of all three founder lines presented with clinical signs of scrapie, indistinguishable from
that of wt control mice, but died after a significantly shortened mean incubation period
Fig 1. PrPC levels and glycosylation profile in healthy wild-type and transgenic mice expressing mutant PrP. (A)
Brain homogenates (10 μg per lane) derived from mice expressing full length mouse wild-type (wt), PrP(H95G) lines 4, 11
and 13, PrP(TetraH>G) line 34 and PrP null controls (Prnp0/0) were subjected to immunoblot analysis using monoclonal
antibody SHA31. Blots were reprobed for β-actin to control for equal loading. Molecular weight is indicated on the left (in
kDa). (B) Removal of N-linked glycans on PrPC encoded by the PrP(H95G), lines 4, 11, and 13 as well as PrP(TetraH>G),
line 34 using peptide N-glycosidase F (PNGase F) and probing of the treated samples with monoclonal antibody SHA31.
fl = full-length PrP.
https://doi.org/10.1371/journal.pone.0188989.g001
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ranging from 87 to 116 dpi (Table 1, "primary passages"). Notably, PrPC expression in both Tg
(TetraH>G) and TgPrP(H95G) lines were comparable to wt levels.
Immunohistochemical analyses
Brain sections from terminally ill RML-infected transgenic and wt control mice were exam-
ined for pathological changes. Wild-type mice (n = 6) presented with spongiform changes that
were prominent in the hippocampus, thalamus, septum, cortex and throughout all white mat-
ter areas (Fig 2A, upper two rows). This was accompanied by distinct synaptic PrPSc deposits.
Diseased TgPrP(TetraH>G) mice demonstrated a wild-type-like distribution of spongiform
changes with considerably less severe spongiosis (Fig 2A, lower two rows, third column). Con-
cordantly, there was a tendency to milder gliosis in some mice (Fig 2A, lower two rows, fourth
column). Immunostaining, however, revealed a PrPSc deposition pattern in TgPrP(TetraH>G)
mice markedly different from the predominantly synaptic pattern seen in wt controls. Instead,
plaque-like accumulations of PrPSc with a dense globular core were observed throughout all
sections, particularly noticeable adjacent to the corpus callosum (Fig 2A, lower two rows, first
and second columns).
Regarding terminally ill TgPrP(H95G) mice, spongiform changes were significantly less
pronounced in all grey and white matter areas analyzed. In all three TgPrP(H95G) transgenic
lines, the most extensive spongiform changes were found in the hippocampus and thalamus,
while cortex and white matter areas were relatively spared (Fig 2B, rows 2–4, third column).
Compared to RML-infected wt mice (Fig 2B, upper row) the thalamus, hippocampus and sep-
tum of TgPrP(H95G) mice were similarly affected by gliosis, whereas the medulla and the tha-
lamic cortex tended to higher or lower scoring values, respectively (Fig 2B, rows 2–4, third
column). Again, striking observations applied to the staining for PrPSc deposits, which in
TgPrP(H95G) mice appeared as feathery plaque-like structures on a faint synaptic background
(Fig 2B, rows 2–4, second column), with accumulations also revealed by the PET-blot tech-
nique (Fig 2B, rows 2–4, first column). The most prominent pathology was recognized in
TgPrP(H95G) mouse line 13, followed by lines 4 and 11. Prior studies have indicated that clin-
ical and pathological manfestations of experimental scrapie disease in mice are little affected
Table 1. Response of transgenic mice and corresponding wt controls to mouse scrapie.
Inoculum Genotype of recipient mice
129/Sv-C57/
BL6
TgPrP(TetraH>G) TgPrP(H95G)
Primary passage
RML 150 ± 12 (n = 8) Line 34: 347 ± 28
(n = 8)
Line 4: 116 ± 3 (n = 8), Line 11: 87 ± 3 (n = 8), Line 13:
89 ± 8 (n = 8)
Secondary passage
TgPrP(TetraH>G)-passaged RML, line HG34
animal #258
160 ± 8 (n = 6) Line 34: 427 ± 12
(n = 8)
Not determined
TgPrP(TetraH>G)-passaged RML, line HG34
animal #260
153 ± 5 (n = 6) Line 34: 372 ± 27
(n = 5)
Not determined
TgPrP(H95G)-passaged RML, line 13 animal #304 150 ± 8 (n = 6) Not determined Line 13: 75 ± 1 (n = 6)
TgPrP(H95G)-passaged RML, line 13 animal #305 152 ± 4 (n = 6) Not determined Line 13: 77 ± 4 (n = 8)
Mean incubation times ± standard deviation in days after i.c. inoculation (dpi) are presented. For primary transmission mice expressing full-length mouse wt
PrP (129/Sv-C57/Bl6) or mutant PrP (PrP(TetraH>G) and PrP(H95G)) were i.c. inoculated with 30 μl of 10% (wt/vol) RML homogenate in PBS. For
secondary passage, brain homogenates from different terminally ill TgPrP(TetraH>G) (line HG34, mouse #258 and 260) as well as TgPrP(H95G) mice (line
13, mouse #304 and 305) were i.c. inoculated in the same lines of recipient mice.
https://doi.org/10.1371/journal.pone.0188989.t001
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Fig 2. Neuropathological changes and PrPSc distribution in hippocampal and cerebellar sections of
prion-challenged mice. (A) First column: Paraffin-embedded tissue (PET) blots demonstrating PrPSc
deposits in hippocampus and cerebellum of RML-infected wild-type (C57/129Sv) and PrP(TetraH>G), line 34
mice. There are plaque-like deposits in and adjacent to the corpus callosum and the internal granular cell layer
of the cerebellum in PrP(TetraH>G) mice. Second column: Corresponding PrPSc immunhistochemistry (upper
field: hippocampus and corpus callosum; lower field: cerebellum; monoclonal antibody CDC1; scale bar:
PrP alleles with mutated histidine residues
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by chronological age of the host [43, 44], indicating that these different patterns of onset and
pathology more likely relate to intrinsic properties of the agent than age-dependent host
responses.
Lesion profiling
Using established protocols, we scored the extent of spongiosis and gliosis within 12 brain
regions of the infected mice in a blinded fashion. These analyses, to assess allelic effects upon
neuropathological endpoints, are shown in Fig 3. With the exception of region 1 (dorsal
medulla), the lesion profiles of spongiform change and gliosis in PrP(TetraH>G) mice occur-
ring after i.c. inoculation of RML were similar in shape but with smaller magnitude than in
non-Tg mice (Fig 3A and 3C). For the H95G allele, the overall profile of lesions resembled wt
mice of the C57/129 genetic background but, again, the intensity of the lesions was attenuated
(Fig 3B); gliosis was similar to wt (Fig 3D).
Immunodetection of PrPSc
Western blot analysis of brain tissue derived from terminally ill transgenic mice revealed that
all animals harboured protease-resistant PrPSc in their brains (Fig 4). TgPrP(TetraH>G) line
34 mice propagated PrPSc with similar ratios of putative di-, mono- and unglycosylated forms
to those seen in RML-infected wt mice (Fig 4A). This was also the case for TgPrP(H95G) mice
descended from three different founder animals (Fig 4B). In terms of quantity, the amount of
PrPSc was notably diminished versus wt for TgPrP(TetraH>G) line 34.
Properties of prions after sequential passage in TgPrP(TetraH>G) and
TgPrP(H95G) mice
We next investigated if sequential passages of a prion isolate in Tg mice resulted in the emer-
gence of novel biological properties. Brain tissues derived from PrP(TetraH>G) and PrP
(H95G) mice that were scored as positive for prion infection (by typical clinical signs, abnor-
mal PrP immunohistochemistry, and the presence of PrPSc on western blot analysis) were used
to i.c. inoculate recipient mice of the same genotype. In one set of analyses, PrP(TetraH>G)
(line 34) and wt mice were inoculated with brain homogenate extracted from two RML-
infected PrP(TetraH>G) line 34 mice. In TgPrP(TetraH>G) mice challenged with PrP(Tetra-
H>G)-passaged prions, the prolonged incubation times observed with the primary transmis-
sion of RML prions in corresponding host mice were again apparent, exceeding 350 days
(Table 1, "secondary passages"). In contrast, wt mice challenged with PrP(TetraH>G)-pas-
saged prions presented with survival times that were not significantly different from the corre-
sponding RML-inoculated group (p = 0.08 for inoculum #258 and p = 0.47 for inoculum
#260); see Table 1, "secondary passages"), indicating no loss in infectious titre.
PrP(H95G) (line 13) and wt animals were infected with brain homogenate derived from
two terminally ill line 13 PrP(H95G) mice. In this secondary passage experiment, a non-signif-
icant trend towards reduced survival times was observed in PrP(H95G) mice compared to the
initial RML-infected group (Table 1, "secondary passages") however, no significant change in
50 μm). Third column: Hematoxylin and eosin stainings (H&E) of hippocampal/corpus callosum and cerebellar
sections demonstrating spongiform changes (scale bars of hippocampus/corpus callosum: 100 μm; of
cerebellum: 200 μm). Fourth column: GFAP immunostaining demonstrating gliosis (scale bars as in third
column). (B) Corresponding histopathological and immunohistochemical examination of hippocampal brain
sections derived from terminally ill PrPH95G mice and corresponding wt controls (scale bars: 200 μm). Three
independent Tg lines (lines 4, 11 and 13) were assessed for these analyses.
https://doi.org/10.1371/journal.pone.0188989.g002
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survival time could be observed with wt mice inoculated with PrP(H95G)-passaged prions
compared to the corresponding RML-infected control group (Table 1, "secondary passages").
Neuropathological lesions and the pattern of PrPSc deposition in the brains of secondary pas-
sage transgenic mice and wt control animals resembled those noted for the corresponding
RML-infected groups (Fig 5). Moreover, western blot analyses of brain tissue derived from
transgenic mice expressing mutant PrP as well as wt mice inoculated with PrP(Tetra-H>G)-
and PrP(H95G)-passaged prions, revealed a banding pattern corresponding to total PrP and
PrPSc, respectively, which resembled the initially RML-infected groups (not shown).
Fig 3. Lesion profiles induced by mouse-adapted scrapie isolate RML in wild-type and transgenic mice expressing mutant PrP. The extent of
spongiform change (A) and reactive gliosis (C) in brain sections of terminally ill wt and PrP(TetraH>G) was assessed semi-quantitatively in a blinded fashion
in nine areas of grey matter and three areas of white matter by lesion profiling. Animals were scored on a scale of 0–5 in each specific area, and mean scores
(n = 6 (C57/129Sv), versus n = 7 (PrP(TetraH>G), line 34), respectively) are shown graphically (error bars plus SD). Blue diamonds: C57/129Sv. Red
squares: PrP(TetraH>G). Analogous data from PrP(H95G) mice are shown in panels B and D (n = 4 (PrP(H95G), line 13), n = 5 (PrP(H95G), line 4) and
n = 7 (PrP(H95G), line 11), respectively); data for C57/129Sv wt animals has been re-plotted for comparative purposes. Blue diamonds: C57/129Sv. Red
squares: PrP(H95G), line 4. Green triangles: PrP(H95G), line 11. Grey circles: PrP(H95G), line 13. Scoring areas as follows: Grey matter: 1, dorsal medulla,
2, cerebellar cortex, 3, superior colliculus, 4, hypothalamus, 5, medial thalamus, 6, hippocampus, 7, septum, 8, medial cerebral cortex at septum level, 9,
medial cerebral cortex at thalamus level. White matter: 1*, cerebellar white matter, 2*, mesencephalic tegmentum, 3* pyramidal tract.
https://doi.org/10.1371/journal.pone.0188989.g003
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Fig 4. Western blot analysis of brain lysates from RML-infected wt and transgenic mice for total PrPC and PrPSc using mono-
clonal antibody 4H11. (A) Brain homogenates from terminally ill wt and PrP(TetraH>G) line 34 mice were either left untreated (- PK) or
subjected to digestion with proteinase K (+ PK). Blots were reprobed for β-actin to control for equal loading. Bands corresponding to total
PrP are marked on the left. Irrelevant lanes have been excised at two positions. Molecular weight standards are given on the right (in kDa).
(B) Corresponding immunoblot analysis of brain homogenates extracted from RML-infected PrP(H95G) mice from the three different lines
11, 13, and 4, respectively, and corresponding wt control (lanes 1 and 2) before (-) and after (+) treatment with PK. Molecular weight
standards are given on the right (in kDa).
https://doi.org/10.1371/journal.pone.0188989.g004
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Fig 5. Neuropathological changes and PrPSc distribution pattern in brain sections of secondary passage transgenic
mice and corresponding wt controls. (A) First column: Paraffin-embedded tissue (PET) blots demonstrating PrPSc deposits
in hippocampus (upper panels) and cerebellum (lower panels) of wt (C57/129Sv) and PrP(TetraH>G), line 34 inoculated with
PrP(TetraH>G)-passaged prions. Second column: Corresponding PrPSc immunhistochemistry (mAb CDC-1). Third column:
Hematoxylin and eosin stainings (H&E) of hippocampal and cerebellar sections demonstrating spongiform changes. Fourth
column: GFAP immunostaining demonstrating gliosis. (B) Corresponding hippocampal brain sections from terminally ill PrP
(H95G) mice (line 13) and corresponding wt controls (C57/129Sv) challenged with PrP(H95G)-passaged prions.
https://doi.org/10.1371/journal.pone.0188989.g005
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In vitro conversion capability of full-length PrP(TetraH>G)
To assess whether extended incubation times in Tg PrP(Tetra-H>G) mice represented a com-
promised ability of the mutant PrPC to convert to the PK-resistant conformation (“PrPres”), we
performed in vitro reactions in the presence of purified brain-derived PrPSc using the method of
Kocisko et al. [4]. In this approach, the altered PrPC variant as well as wild-type PrPC from
mouse were expressed in PrPC-deficient cells in the presence of 35S-methionine and 35S-cysteine,
purified by immunoprecipitation, and used together with purified PrPSc from RML infected
mouse brain for in vitro conversion reactions. We found that substitution of all four OR histi-
dines reduced the conversion efficiency obtained with wt PrP almost two-fold (Fig 6A; p = 0.07
and 0.03 using two-sided and one-sided T-test analyses, respectively). There was no detectable
PrPres in unseeded reactions (Fig 6B), indicating that neither mouse wt PrP nor PrP(TetraH>G)
developed intrinsic resistance towards proteinase K digestion under these assay conditions.
Single molecule analysis of glycine-substituted PrP alleles
In a final set of analyses, we assessed the ability of single molecules of recombinant full-length
wt PrP and the two mutant proteins to undergo structural conversion and aggregate formation
in the presence of putative co-factors [45, 46]. To quantify and characterize rPrP aggregates
formed, we used fluorescently-labelled PrP and cross-correlation analysis as well as scanning
for intensely fluorescent targets in a confocal single molecule detection system, as described
previously for recombinant full-length human PrP [42]. The use of single particle fluorescence
in combination with a measurement setup optimized for high-throughput measurements in
multi-well plates allowed a large number of individual measurements to be performed, a
potentially advantageous approach given inherent variability often observed in assays of de
novo protein aggregation.
Fig 6. Conformational changes measured by in vitro conversion reactions. (A) In vitro conversion reactions have been
performed with radiolabeled wild-type and PrPC(TetraH>G) purified from RK13 cells and PrPSc purified from brains of RML-infected
Tga20 mice as described [4]. Samples were analyzed by SDS-PAGE-fluorography, and relative conversion efficiencies (CVE) were
calculated from band intensities before and after digestion with proteinase K using the formula CVE [%] = [I˚+PK / (I˚-PK*10)]*100.
PrPC with substituted OR histidines (PrPC(TetraH>G)) is only half as efficient in converting to the misfolded, PK-resistant conformer
than wt PrPC. Mean values ± standard error (SEM) were determined from 11 independent experiments for each PrPC type. P-values
(p (two sided) = 0.07, p (one sided) = 0.036) were obtained by T-Test calculation. (B) Control reactions performed in the absence of
PrPSc seed.
https://doi.org/10.1371/journal.pone.0188989.g006
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Wild-type rPrP and the two mutant proteins (i.e. TetraH>G-rPrP and H95G-rPrP) were
all found in the non-aggregated state in 0.2% SDS at pH 7.2 in the absence of additional copper
(S4 Fig, "0.2% SDS"), the results for the wt allele being anticipated from prior studies [45, 46].
After SDS was diluted out below 0.05% to induce aggregate formation, an increase in the
cross-correlation amplitude was observed, which is a direct measure for the presence of dou-
ble-labeled particles present in the sample, and is thus indicative of de novo oligomerization.
Thus, at SDS-concentrations of 0.02%, wt rPrP reached a significant higher cross correlation
amplitude than TetraH>G-rPrP and in particular H95G-rPrP (Fig 7, "0.02% SDS"), indicating
that the mutations reduced the oligomerization propensity of wt PrP.
Disturbances in the levels of copper and manganese have been described in prion-infected
brain tissue [47–49] and changes in brain copper levels have been suggested to influence incu-
bation time in experimental prion disease [11, 13]. To assess whether metal ions such as Cu2+
and Mn2+ affect the aggregation properties of wt and mutant rPrP, we added different
amounts of CuCl2, MnCl2, and EDTA to aggregation reactions in the presence of the 0.02%
concentration of SDS that is permissive to formation of PrP multimers. As shown in Fig 7, in
the presence of 0.02% SDS, copper concentrations of 1 μM (in molar excess to recombinant
protein) repressed the aggregation of wt-rPrP about 70%, whereas the aggregation of both Tet-
raH>G-rPrP and H95G-rPrP was less affected (Fig 7, "1 μM Cu2+"). Higher copper concentra-
tions (10 μM and 50 μM) were able to further decrease the aggregation efficiency of wt-rPrP
but again showed no significant effect when added to mutant rPrPs (data not shown). These
data indicate that sequences within and adjacent to the OR region in unmetallated PrP (i.e.,
apo-PrP) facilitate aggregation, but this effect is offset by metallation. TetraH>G-rPrP and
Fig 7. Conformational changes measured by fluorescence correlation spectrometry (FCS). The y-axis represents the
G(0), two-color cross-correlation amplitude values. In vitro aggregation of recombinant full-length mouse wild-type or mutant
PrP analyzed by FCS. Wild-type (wt-rPrP, black columns) and mutant rPrP (TetraH>G-rPrP, purple columns, and H95G-
rPrP, blue columns) showed no aggregation at 0.2% SDS. Decreasing the SDS concentration to 0.02% resulted in
aggregation of all recombinant proteins to a different extent, being highest with wt-rPrP and lowest with H95G-rPrP. Addition
of metal ions like copper (Cu2+) and manganese (Mn2+) as well as depletion of divalent metal ions with EDTA in the
presence of 0.02% SDS had a much stronger impact on the aggregation of wt-rPrP than on TetraH>G-rPrP and H95G-rPrP.
Data are shown as mean values of last five meanders ± SEM of four to six independent experiments with four replicates
each.
https://doi.org/10.1371/journal.pone.0188989.g007
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H95G-rPrP assessed under the same conditions have lower baseline measures for aggregation
that are little affected by Cu2+ addition. To assess whether a reported stimulatory effect of Mn2+
on aggregation of human rPrP(23–231) [42] is also applicable for full-length mouse rPrP, we
added MnCl2 in the same type of protein aggregation experiments. We found that manganese
concentrations of 30 μM were able to further increase the aggregation of full-length wt rPrP by
~15%, with a mild proportional increase noted for the TetraH>G-rPrP allele but not the H95G-
rPrP allele (Fig 7, "30 μM Mn2+"). To assess whether the buffer used for aggregation assays con-
tained traces of divalent metal ions that affect outcome measures, we performed controls using
the chelating agent EDTA. In the presence of 100 μM EDTA wt-rPrP aggregated ~40% less than
with 0.02% SDS alone (Fig 7, columns labelled “100 μM EDTA”). Addition of the chelating
agent did not completely abolish the inhibitory effect seen with Cu2+, nor the stimulating effect
seen with Mn2+. Again, no affect was seen on the aggregation of the mutant proteins.
Taken together, our data indicate that H>G replacements in the OR region and at position
95 resulted in a decreased tendency for aggregation of full-length mutant proteins versus the
wt point of reference.
Discussion
Multiple activites of the PrPC OR
Prior work has defined complex relationships between the PrPC OR region and prion disease
pathogenesis. Though the OR region comprises the main Cu-binding region of PrPC, accom-
modating up to 4 Cu (II) ions per polypeptide chain, a direct causative link between copper
and prion disease was challenged by the observation that transgenic mice completely lacking
the OR region (PrPΔ32–93) were still susceptible to infection with laboratory prion isolates
[6]. Elimination of the OR region slowed the rate of disease progression in these transgenic
mice, indicating that the octarepeats are not necessary for sustaining prion replication and
pathogenesis, but do modulate the extent of neuropathological degeneration and disease pre-
sentation. Genetic prion diseases are associated with extra octarepeats (i.e., above the typical
wt complement of one histidine-lacking OR followed by four histidine-containing ORs), with
these mutant PrP alleles likely originating from replication fork slippage on tandem direct
repeats during DNA replication. For these open reading frame expansions, the more octapep-
tide repeats are present in PrP, the more prone the protein is to misfolding [50, 51], which cor-
relates with earlier disease onset and shorter disease duration in affected patients [52]. Also,
when supernumerary octarepeat insertions rise above a threshold, they give rise to GSS-like
disease with cerebral amyloid deposition instead of the clinical picture of familial CJD [53].
This effect, seen with histidine-containing wt OR units, has been ascribed to a conformational
aspect of metal-binding to the OR region, where insertions impede the ability to transition
from a configuration denoted "component 3" to a multivalent configuration, "component 1"
[54]. Overall, an extensive literature contains complex, and sometimes contrasting, findings
[55–58]; taken together one may surmise that the OR region has pleiotropic effects, i.e. modu-
lating prion replication and pathogenicity, as well as producing a protective effect against oxi-
dative stress [59, 60] and modulating copper-dependent multimerization [61]. To address
these complex relationships and the in vivo role of site 5 we created two new strains of trans-
genic mice. The resulting Tg lines revealed a number of unexpected features as well as some
parallels to mice with structure-guided re-design of the PrP OR region [26].
Biological properties of PrP(TetraH>G)
We made a line of PrP(TetraH>G) mice that expressed PrPC at a level slightly less than that
seen in wt control animals. Here, the histidine to glycine substitutions within the OR region
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did not influence α-cleavage in the brain to make C1 fragment (Fig 1); others have noted that
copper-stimulated PrP internalization requires both the octapeptide repeat domain and the
palindromic sequence starting at the α-cleavage site (amino acids 110/111 in mouse PrP) to be
intact [18, 23, 62]. In terms of cell biological effects, PrP(TetraH>G) had a diminished capacity
to initiate cell death when exposed to an environment containing PrPSc and under cell culture
conditions without copper-supplementation, PrP(TetraH>G) trafficked to lipid rafts like wt
PrPC (S2 and S3 Figs). While we cannot exclude that Cu-dependent endocytosis would be
impaired for this allele, this process has been modeled in other studies by supplementation of
culture medium with copper concentrations of 100–500 μM, considerably higher than for the
other studies described here [23, 63].
For the biology of metal speciation, Miura et al. have suggested that a possible role of the wt
octarepeat motif is to stabilize the α-helical structure of PrPC in the presence of copper [64].
Also, using hybrid density functional theory (DFT) calculations, Hodak et al. have inferred
that at physiologically-relevant low Cu(II) concentrations, a structural alteration of the Cu-
bonded octarepeat region creates flexible turns in the areas separating copper-bound residues,
which increases the rigidity of the entire N-terminal domain to make it more resistant to mis-
folding [12]. On the other hand, and bearing in mind that mature wt PrPC is normally consid-
ered to exist a monomer, Yen et al. reported that copper-induced structural conversion of wt
PrPC predisposes it for oligomerization that is associated with toxicity [58]. Thus, we arrive at
opposite predictions that in the presence of copper, the OR region of the PrP(TetraH>G) allele
is now susceptible to misfolding under low Cu(II) occupancy or is prevented from Cu-depen-
dent oligomerization. In practice, and making an assumption that PrPC can become charged
with endogenous bioavailable metal [65], we could not detect a spontaneous neurodegenera-
tive disease in the aged PrP(TetraH>G) Tg mice (not shown). In the case of prion-infection
initiated with i.c. delivery of PrPSc—a situation where PrPC does misfold and multimerize—
replacement of the four wt histidine residues within the OR region with glycine residues
resulted in prolonged survival times of scrapie-infected PrP(TetraH>G) mice (Table 1). These
results fit well to the finding that treatment of mice with the copper chelator D-penicillamine
(D-PEN) delays onset of prion disease [13]. In addition, the diseased animals show reduced
PrPSc levels and serial passage of infectivity from the brains of mice with end-stage disease
resulted in prolonged incubation times in comparison to the parental stock of RML prions,
indicative of a drop in infectious titre. Our overall results with PrP(TetraH>G) line 34 mice
indicate that the amino acid exchange not only influenced the OR itself but also induced a per-
sistent conformational change in the C-terminal protease-resistant core portion of the protein.
These results can be reconciled with our in vitro data showing that recombinant PrP(Tetra-
H>G) was less susceptible to SDS-induced aggregation than wt rPrP, and that cellular PrP
(TetraH>G) had a reduced propensity for conformational in vitro conversion to the protease
resistant isoform (Figs 6 and 7, S4 Fig). Perhaps most remarkably, we found plaque-like PrPSc
deposits with a dense globular core in infected TgPrP(TetraH>G) mice. A second PrP(Tetra-
H>G) Tg line designated HG1-2CL was profiled less extensively but behaved in a similar man-
ner to line 34 in the accumulation of plaque deposits (as well as protease-resistant PrP profile
after RML inoculation and in the PMCA conversion assay; not shown). As the dimorphism
L108F, T189V that defines the mouse Prnpb allele is typically required to allow certain prion
isolates to make amyloid plaques in mice [44, 66, 67], this phenomenon is most unusual for
prion infections where the PrPC precursor has C-terminal sequences identical to the mouse
Prnpa allele.
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Biological properties of PrP(H95G)
In contrast to the prolonged incubation times observed with scrapie-infected PrP(TetraH>G)
mice compared to wt mice, TgPrP(H95G) mice had more rapid disease progression. Cox et al.
have suggested from ab initio electronic structure calculations of rPrP(89–230) that detach-
ment of copper bound to H95 might be a pivotal step in the conversion pathway [68]. Accord-
ing to this model, ablation of copper binding to H95 with Ala, Tyr or Gly substitutions should
present with shortened incubation times; for the H95G allele here, this was indeed the case
(Table 1). In vitro analyses of site 5 mutations using extended X-ray absorption fine structure
spectroscopy (EXAFS) along with studies in cultured cells provided some overlapping findings
and conclusions [69]. These authors showed enhanced PK-resistance of an epitope-tagged
mouse PrP equivalent to H95Y when expressed in chronically infected neuroblastoma cells
and also that this allele expressed in uninfected cells generated misfolded PrP that could "seed"
uninfected recipient N2a cells. These studies proposed a mechanism underlying these effects
wherein a pH drop caused by trafficking into endosomal/lysosomal compartments causes
H95Y PrP to "switch" to a pathological conformation with enriched β-sheet content in the seg-
ment spanning residues 105–116 and the adjacent palindromic motif. Conversely, WT PrP
with the non-OR site 5 region coordinated in the 2His state (i.e. copper coordinated by His95
and His110) is stabilized by an attenuation of contacts between residues 89–126 and the C-ter-
minal structured domain. Furthermore, according to the computational model in Cox et al.,
copper coordination to H95 can protect PrP from prion conversion as in their copper binding
at this position is not compatible with formation of β-strands in a model for PrPSc involving
left-handed helices [68]. However, not exactly in accord with these in silico and in vitro analy-
ses [68, 69], the shortened disease progression noted in TgPrP(H95G) mice could neither be
ascribed to an increased tendency to undergo structural conversion and aggregate formation
triggered by a reduction of SDS concentration from 0.2 to 0.02% in an in vitro system, nor to
increased PrPSc levels in the brains of terminally ill mice (assessed by western and PET blot
analyses, respectively). Given that PrPSc itself is not necessarily the primary cause of neurode-
generation and that aggregation, toxicity and infectivity are distinct processes (summarized in
[70]), it appears either that PrP(H95G) aggregates are more toxic than aggregated wt (or for
that matter PrP(TetraH>G)) or that copper depletion at position 95 may play a role in confer-
ring PrPSc neurotoxicity. In accord with the concept of altered toxic behaviour, diffuse PrP
deposition observed in TgPrP(H95G) mice differed from the synaptic pattern seen in scrapie
infected wt mice and, in contrast to TgPrP(TetraH>G) mice, more closely resembling genetic
human prion diseases arising from point mutations in the C-terminal domain [71].
Relationships between PrP N-terminal function and disease
pathogenesis
Although studies here and in a related paper [26] were undertaken to explore different predic-
tions from in vitro studies, overlaps were seen in outcomes measured in the brains of Tg mice.
The PrP(S3) allele made by Lau et al. has changes (within each OR of the OR region) that will
accentuate and lock "component 3" binding geometry [26]; this geometry is associated with
nM Cu-binding affinity and a metal: polypeptide stoichiometry of 1:1. A PrP S1 allele made by
Lau et al. has a different OR region alteration to disfavor this type of copper binding. Here, the
PrP(H95G) substitution C-terminal to the OR region was designed to attenuate “site 5” copper
binding (also with a metal:polypeptide stoichiometry of 1:1 and which has a Kd estimated
between 10−9–10−14 M in its wt form [72, 73]). In practice, and accommodating for transgene
expression levels, both PrP(S3) and PrP(H95G) alleles led to curtailed incubation periods
upon prion inoculation, with a focus upon altered toxicity rather than elevated infectious titre;
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indeed, serial passage of infectivity and lower spot counts in a scrapie cell assay indicated
depressed infectious titres for PrP(S3) [26] while inocula from TgPrP(H95G) mice produced
typical incubation times in wt mice (Table 1). For PrP(TetraH>G) and PrP(S1), these alleles
were designed to alter the OR region in different ways: in the case of PrP(TetraH>G), to
remove OR histidines and prevent any metallation (and hence any metal-dependent structural
compaction) of the OR region while in the case of PrP(S1), to hold all histidine-containing
OR’s in an extended conformation [25, 26]. Here, in practice, and again accommodating for
transgene expression level, both alleles were associated with reduced PrPSc levels, reduced titre
and prolonged incubation times subsequent to prion inoculation.
One school of thought is that distinct redox activites of PrP are involved in the mechanisms
underlying prion diseases by modulating reactions leading to ROS-mediated β-cleavage and
initiating beta-sheet formation. However, the finding that cleavage in the vicinity of the β site
can be greatly enhanced by a process independent of metal binding to the OR region [26, 74]
gives pause to the view that redox processes are necessarily front and centre in PrP biology.
Instead, conformational changes may lie to the fore. While the OR region and site 5 are
natively unstructured in apo-PrP, we conclude that cis interactions between the OR region or
the region corresponding to site 5 and the globular C-terminal domain can modulate patho-
genic outcomes. This conclusion is based in part upon in vitro studies where the OR region in
zinc-loaded PrP interacts with negatively charged residues on helices 2 and 3 [75] and where
Cu-loaded OR region (in component 3 geometry and with site 5 inactivated by histidines to
tyrosine replacements) interacts with helix 3 [76]. Using a different approach, Thakur et al.
inferred that in the presence of copper the PrP OR region interacts with helix 2 and the site
5 region interacts in cis with helix 1 and the preceeding loop [77]. For the folding of PrP
expressed in the brain, the PrPSc from TgPrP(S3) mice with an altered OR had a change in
accessibility of the 12B2 epitope at residues 89–93 closely adjacent to H95 [26] and cis effects
upon the globular domain could be inferred from altered infectivity titres, proteinase K-resis-
tance and responses in conformational stability assays. We infer that similar long-range
remodeling effects likely drive the outcome measures in Tg.PrP(TetraH>G) and Tg.PrP
(H95G) mice. Moreover, since the vicinity of site 5 is also a major binding site for PrPC/oligo-
meric Aβ interactions [78, 79] further work to understand these interactions may be useful
above and beyond the immediate context of prion infections.
Supporting information
S1 Fig. Wt-like properties of the PrPTetraH>G allele assessed in Tg mice. TetraH>G line
34 mice did not develop cerebellar lesions or dysmorphology that distinguished them from
non-Tg control wt C57/129Sv mice.
(TIF)
S2 Fig. Cellular localization and expression level of full-length mouse wt PrPC or Tetra-
H>G PrP expressed in RK13 cells. (A) Expression level and glycosylation pattern of wild-
type and mutant PrP in RK13 (left panel) respectively, monitored by Western blot analysis
using monoclonal antibody 6H4 after SDS-PAGE of whole cell lysates before (-) and after (+)
treatment with PNGase F. Molecular weights are indicated on the left (in kDa). (B) Localiza-
tion of wild-type and mutant PrP to lipid rafts. RK13 cells transfected to express full-length
mouse PrP (left panel) or PrP(TetraH>G) (right panel) were cultivated to confluence and then
placed on ice or kept at 37˚C. Sucrose gradient flotation was done with cell lysates. Aliquots of
each fraction collected from the top of the gradient were precipitated, subjected to SDS-PAGE
and immunoblot analysis using antibody RA3153. Dot Blot analysis with horseradish-peroxi-
dase conjugated cholera toxin subunit B (Molecular Probes1, Leiden, Netherlands) was
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performed to detect the lipid rafts containing fractions.
(TIF)
S3 Fig. Co-cultivation assay for determining toxic effects of PrPSc. (A) SH-SY5Y cells
expressing full-length wild-type PrP (PrP), or PrP(TetraH>G), PrP(H95G) or GPI-coupled
GFP (GPI-GFP) were co-cultured with prion-infected (ScN2a) or uninfected neuroblastoma
cells (N2a) for 16 h. For quantification of apoptotic cell death, SH-SY5Y cells were fixed, per-
meabilized and stained for active caspase-3. The percentage of apoptotic cells among trans-
fected cells is shown. (B) Expression of transfected constructs analyzed by Western blotting
using the anti-PrP antibody 4H11 or an anti-GFP antibody. Molecular weights (kDa) are given
on the left.  p< 0.0005.
(TIF)
S4 Fig. In vitro conversion of PrP with disrupted copper binding sites within the OR region
using protein misfolding cyclic amplification (PMCA). Prior to PMCA, healthy brain
homogenates were adjusted to 60 ng PrPC/μl with 10% (wt/vol) PrP0/0 brain homogenate,
spiked 1:50 with 10% (wt/vol) RML homogenate and subjected to 10 rounds of PMCA. In
vitro generated wt PrPres (C57/129Sv; lanes 1–4), PrPres(TetraH>G) lines 34 (lanes 5–8), as
well as PrPΔ32–93 (C4; lanes 9–12) was detected using monoclonal antibody 4H11. In order
to rule out degradation of PrPC before PMCA, the corresponding undigested starting material
was loaded as control (lane 13: wt; lane 14: PrP(Tetra H>G), line 34, lane 15: C4). Molecular
weights are indicated on the right (in kDa). All samples were blotted onto the same membrane
and exposed for the same amount of time; irrelevant lanes have been excised at two positions.
(TIF)
S1 Text. Supporting material and methods.
(DOC)
S2 Text. Supporting results.
(DOC)
S3 Text. Supporting references.
(DOC)
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